Nowe wytyczne eradykacji Helicobacter pylori – 5 faktów, które należy znać Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
Helicobacter pylori, eradykacja, inhibitory pomy protonowej
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono metody rozpoznawania zakażenia Helicobacter pylori z uwzględnieniem zasad wyboru testów inwazyjnych i nieinwazyjnych. Opisano aktualne wytyczne dotyczące wyboru schematu leczenia eradykacyjnego oraz nowe dane na temat podawania określonych probiotyków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska, A. (2024). Nowe wytyczne eradykacji Helicobacter pylori – 5 faktów, które należy znać . Medycyna Faktów , 17(1(62), 7-10. https://doi.org/10.24292/01.MF.0124.01
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zamani M, Ebrahimtabar F, Zamani V et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018; 47: 868-76.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon (FR): International Agency for Research on Cancer. IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 1-241.
3. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022, 71: 1724-62.
4. Jaroń K, Pietrzak A, Daniluk K et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
5. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017; 112: 212-39.
6. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016; 151: 51-69.e14.
7. Kuo CH, Lu CY, Shih HY et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014; 20: 16029-36.
8. Nyssen O, Bordin D, Tepes B et al. European registry on Helicobacter pylori management (HP-EUREG): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021; 70: 40-54.
9. Yang C, Liang L, Lv P et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021; 26: e12856.
10. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015; 41: 1237-45.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon (FR): International Agency for Research on Cancer. IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 1-241.
3. Malfertheiner P, Megraud F, Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022, 71: 1724-62.
4. Jaroń K, Pietrzak A, Daniluk K et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Gastroenterology Rev. 2023; 18(3): 225-48.
5. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017; 112: 212-39.
6. Fallone CA, Chiba N, van Zanten SV et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016; 151: 51-69.e14.
7. Kuo CH, Lu CY, Shih HY et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014; 20: 16029-36.
8. Nyssen O, Bordin D, Tepes B et al. European registry on Helicobacter pylori management (HP-EUREG): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021; 70: 40-54.
9. Yang C, Liang L, Lv P et al. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021; 26: e12856.
10. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015; 41: 1237-45.